Latest News

Joint Team Effort Succeeds in Advancing First-in-Cass Triple Combination Immunotherapy to Studies in Patients with Colorectal Cancer

AMAL Therapeutics and ViraTherapeutics, in partnership with their common parent company, Boehringer Ingelheim, are very proud to announce that they have advanced their first-in-class heterologous prime-boost vaccine to Phase 1 studies in patients...